2015 American Society of Clinical Oncology Annual Meeting*

May 29-June 2, 2015; Chicago, Illinois
Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, review data from key presentations on immunotherapy from the 2015 clinical oncology meeting in Chicago.
Michael Atkins Headshot
Michael B. Atkins, MD
David F. McDermott, MD
Daniel P. Petrylak, MD
Antoni Ribas, MD, PhD
person default
Naiyer Rizvi, MD
person default
Heather Wakelee, MD

Immunotherapy

Results of this genomic and molecular study suggest that the lack of spontaneous immune infiltration in some melanomas is not due to lack of tumor antigens.

Released: June 3, 2015

Patients with BRAF-mutant melanoma who received treatment with MEDI4736 + trametinib + dabrafenib showed robust immune activation and promising objective response rate.

Released: June 3, 2015

This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.

Released: June 4, 2015

Updated results from a phase Ib dose-expansion study in UBC suggest that the anti–PD-L1 antibody atezolizumab yields greater efficacy in patients with higher expression of PD-L1 on immune cells.

Released: June 5, 2015

Updated data from the urothelial cohort that demonstrate favorable and durable activity of pembrolizumab.

Released: June 5, 2015

In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.

Released: June 1, 2015

Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.

Released: May 31, 2015

Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.

Released: June 1, 2015

Core faculty, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.

Michael Atkins Headshot Michael B. Atkins, MD David F. McDermott, MD Daniel P. Petrylak, MD Antoni Ribas, MD, PhD person default Naiyer Rizvi, MD person default Heather Wakelee, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: August 25, 2015 Expiration: August 24, 2016

In this downloadable slideset, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.

Released: August 25, 2015

Data from this large phase III trial suggest that the combination of nivolumab + ipilimumab offers better efficacy vs ipilimumab alone, but also better efficacy vs nivolumab alone, particularly for patients whose tumors are low in PD-L1 expression.

Released: June 2, 2015

Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.

Released: May 31, 2015

Results of a phase1/2 study of nivolumab monotherapy in patients with advanced hepatocellular carcinoma reveal encouraging 12 month survival rate

Released: May 31, 2015

Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.

Released: May 31, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?